Tuesday, April 26, 2022

"Australia's #1" is puffery for product sourced from but not sold in Australia

Painaway Australia Pty Limited ACN 151 146 977 v. MaxRelief USA, Inc., 2022 WL 1028024, No. 18-3854 (E.D. Pa. Apr. 6, 2022) [not so sure the ACN should be part of the caption, but there it is in Westlaw]

Painaway sells a range of arthritis and pain relief spray, cream, and roll-on products; it is registered with the Australian Therapeutic Goods Administration (TG”), Australia’s regulatory agency for medical drugs and devices and sells to consumers inside and outside of Australia, via its website.

MaxRelief sells pain relief spray and cream through its website and through online distributors such as Amazon.com and retail pharmacies. MaxRelief used to surce pain relief spray products in Australia from a non-party, but stopped in 2014.

Painaway advertised its products as “Australia’s No. 1 Joint & Muscle Spray and Cream Topical Pain Relief Brand” on: (1) its Australian website; (2) social media; and (3) Ultimate Fighting Championship (“UFC”) athletes’ clothing in matches televised in the United States. Around 2013, MaxRelief also made “Australia’s # 1” claims through its website, Twitter, and YouTube accounts. It also used radio and television outlets in select US markets. Its witness testified that, “at the time [MaxRelief] was made in Australia, it was manufactured – it was invented in Australia, and we believed it to be the best product – the best pain relief product of Australia. [ ] – we didn’t say we were the #1 selling, we didn’t say – and to be honest with you, we didn’t give much thought to it, other than we’re probably Australia’s best product – Australia’s best pain relieving product, and that’s what we say.”

MaxRelief stopped using the “Australia’s # 1” advertising slogan in 2018; Painaway advised Defendant’s customers that MaxRelief used “Australia’s #1” slogan in violation of an injunction order issued, via default, in E.D. Pa., but MaxRelief wasn’t a party—Painaway sued and obtained the injunction against its Australian supplier.

Painaway then sued, alleging that MaxRelief’s use of the “Australia’s #1”  was explicitly false and misleading, as MaxRelief’s products are not sold in Australia.

The court granted summary judgment to MaxRelief.

First, “Australia’s #1” was puffery, despite the geographical reference and the lack of sales in Australia. The court, wrongly, began by focusing on intent: MaxRelief chose the slogan for “subjective reasons.” There was nothing quantifiable in the claim, like best selling or best ingredients. “[B]ecause it is unquantifiable, ambiguous, and vague, it cannot be determined to be literally false, and instead, is puffery.” Nor did the slogan specify a “specific person or identifiable group” that favored the product.  “Defendant sourced the materials and products from Australia; thus, without adding specifics as Defendant did here, MaxRelief is allowed to safely make this broad and vague claim that it was ‘Australia’s #1’ within the confines of puffery.”

Plaintiff also failed to show consumer deception or materiality. Nor did it show sales diversion, since the evidence was that plaintiff’s sales in the US were “insignificant” before MaxRelief entered the market.

 


court declines to decide between Eveready and Squirt and lets a linguist in too

Therapeutics MD, Inc. v. Evofem Biosciences, Inc., 2022 WL 1013285, No. 20-CV-82296-RUIZ/REINHART (S.D. Fla. Mar. 30, 2022) (R&R)

The parties cross-moved to exclude each other’s experts who conducted consumer surveys to determine the likelihood of confusion between plaintiff’s mark (IMVEXXY) and defendant’s mark (PHEXXI).

An Eveready survey doesn’t prompt respondents with the plaintiff’s mark, only the accused product; it is “appropriate for testing alleged infringement [of] a ‘top of mind’ mark: one that is ‘highly accessible ... in memory, enhancing the likelihood that it will be cognitively cued by a similar junior use.’ ” It uses open-ended questions to detect assocation. A Squirt survey, by contrast, presents the consumer with multiple competing products, including the parties’ marks, and asks consumers whether they believe any two of the products are offered by the same company. The Squirt test’s “use of closed-ended and leading questions has been criticized by both courts and commentators because of the suggestive nature of those questions.” In addition, a Squirt study is less effective “when the consumer is presented with the competing products in a manner different than how those products appear in the actual marketplace.” “Nevertheless, experts who have conducted Squirt surveys are routinely permitted to present their findings to juries.”

Plaintiff’s Squirt survey found net confusion among providers/patients of approximately 20% between IMVEXXY and PHEXXI. Defendant’s Eveready survey found no material likelihood of confusion.

The Squirt survey: 300 prescribers and 800 patients saw plaintiff’s mark, IMVEXXY, “as seen in the real-world marketplace.” Then the survey posed “distraction questions” intended to “creat[e] a buffer period” and “reduce[ ] any potential order-effect bias” so that IMVEXXY receded from the respondents’ immediate short-term memory before being asked questions about other products. The prescriber test group was shown product samples of PHEXXI followed by two control brands (Lo Loestrin and Premarin), while the prescriber control group was shown LEPHEL2 followed by the same control brands. The patient-respondents saw the same product samples and product brochures. Questions asked whether they believed the products were “made by”; were “affiliated with or sponsored or approved by”; and “[r]equires permission or authorization from” “the company whose product you were shown in the first section of the survey.”

Defendant argued that Squirt was inappropriate given that prescription drugs are not presented to patients in the marketplace in close proximity to each other. It also argued that the survey failed to replicate market conditions by showing respondents actual product packaging, failed to randomize the order of the stimuli which “artificially inflated the level of confusion,” asked leading questions, and failed to use control names similar to the marks at issue. Defendant also argued that the only relevant consumers were physicians and pharmacists.

Eveready: 209 qualifying pharmacists were first asked to review a particular name in the context of “a pharmaceutical drug for women’s sexual and reproductive health.” The test cell used PHEXXI and the control used LEPHEL. Questions asked respondents to identify any brand or company that they believed (a) to be the source of the named drug, or (b) to be affiliated/connected with the named drug, or (c) needed to give permission or approval to the named drug. The survey also asked the pharmacists to identify any other pharmaceutical drugs they believed were put out by the same company or brand that puts out, or were affiliated/connected with, or needed to give permission/approval to the named drug. None of the participants named plaintiff or IMVEXXY. Pharmacists were chosen because, the surveyor reasoned, prescription drugs are controlled by prescribers, and pharmacists review and dispense the prescription.

In a rebuttal report, defendant’s expert did the same Eveready survey again, with 200 prescribers of contraceptive drugs, still with zero confusion.

Plaintiff argued that Eveready was inappropriate because despite IMVEXXY being a “strong brand” that has been “out for a few years in the market,” it has “not achiev[ed] a top-of-mind awareness” because the “level of marketing ... is minute.” In addition, defendant’s survey didn’t show product packaging to the survey participants and, plaintiff argued, used leading questions that wrongly limited the respondents’ thinking to drugs prescribed only for “women’s sexual and reproductive health.”

Finally, defendant’s expert did a modified Squirt survey with different randomization procedures, showing respondents the product packaging for IMVEXXY and PHEXXI as they are sold commercially (as opposed to product samples), and showing all six sides of the packaging. This, defendant argued, found “the absence of confusion” among prescribers, though plaintiff argued that it showed the prescribers packaging that they do not encounter in the marketplace.

The court decided to leave it all for the jury. Courts have accepted both methodologies, and the flaws in each one will be presented to the jury because both types will be offered to them. “Simply put, each party has satisfied its burden of showing that its expert should not be excluded based on Daubert.”

The court also declined to exclude the testimony of  a linguist with over 35 years of experience about the alleged orthographic and phonetic similarities of IMVEXXY and PHEXXI; she opined that the marks share numerous similarities, “including (i) similar letters; (ii) similar sounds; (iii) similar word stresses; (iv) interchangeability of some of the sounds; (v) unique distribution of other sounds (such as -xx-); and (vi) auditory weakness of the first syllable – [that] make it difficult to distinguish PHEXXI from IMVEXXY.”  [Ah, drugs with X in them, reminds me of my favorite case; search the opinion for "Mexican" to find the best anecdotal takedown of a statistical model you will ever read.] She was qualified to testify to those things and provided an adequate basis for her conclusions, and her testimony could help the jury, though her criticisms of the FDA and USPTO’s processes for approving drug names were stricken. Plaintiff didn’t show she was qualified to do that and her testimony wouldn’t help the factfinder.

Plaintiff was also allowed to present an expert on the costs of corrective advertising claimed as damages. Defendant’s expert could counter that, and was qualified to do so notwithstanding his lack of familiarity with judicial precedents on corrective advertising. He could also provide an alternative damage calculation based on an imputed royalty, which addressed the same subject matter—damages—to which plaintiff opened the door.

advertiser class certified in case about Meta's overclaiming of "Potential Reach" of ads

DZ Reserve v. Meta Platforms, Inc., 2022 WL 912890, No. 3:18-cv-04978-JD (N.D. Cal. Mar. 29, 2022)

The court certified a class of United States residents who paid Meta for placement of advertisements on social media platforms based on Meta’s allegedly inflated claims of ad reach resulting in artificially high prices, resulting in claims for fraudulent misrepresentation and fraudulent concealment (for damages) and under the UCL for injunctive relief.

Meta’s Ads Manager displays a “Potential Reach” for an ad after advertisers select their targeting and placement criteria; the default for people in the United States aged 18 and up was over 200 million people, revised as demographic targeting criteria are selected. “Meta describes the Potential Reach as an estimate of people in the ad’s target audience.”

Typicality: Meta argued that the proposed class included a diverse population of advertisers ranging from “ ‘large sophisticated corporations’ to ‘individuals and small businesses,’ ” meaning that the named plaintiffs, as advertisers on the smaller end of the spectrum, couldn’t fairly or adequately represent them. The court disagreed. Typicality is demonstrated when “the claims or defenses of the representative parties are typical of the claims or defenses of the class.” Plaintiffs had evidence that, regardless of size or buying power, Meta’s customers saw similar representations by Meta about its advertising reach and programs. Advertisers were shown the same default Potential Reach of over 200 million people before they applied any targeting criteria, and plaintiffs’ expert testified that advertising customers were shown Potential Reach estimates that were inflated by a similar percentage. Differing advertising budgets and scope of purchases didn’t defeat typicality or adequacy.

Nor could Meta successfully recast its typicality and adequacy challenges as questions of reliance and UCL standing is equally unavailing. “[P]laintiffs demonstrated reliance by proffering evidence that DZ Reserve was deterred from using Meta ads after learning that the Potential Reach was an inaccurate metric;” plaintiffs indicated that “they would have spent less on ads after learning the Potential Reach was inaccurate, demonstrating that they were deceived into spending more money.” This was enough for reliance for UCL standing purposes.

Nor did an arbitration provision in contracts for advertising after May 2018 defeat adequacy and typicality. The case was filed in August 2018, but Meta never sought to compel arbitration, and might have waived it; anyway, the named plaintiffs purchased ads before and after May 2018, making them adequate for both situations.

Commonality/predominance: The main liability issues were common to the class members and are capable of resolution with common evidence. Fraudulent concealment and fraudulent misrepresentation claims require: “(a) misrepresentation (false representation, concealment, or nondisclosure); (b) knowledge of falsity (or ‘scienter’); (c) intent to defraud, i.e. to induce reliance; (d) justifiable reliance; and (e) resulting damage.” For plaintiffs’ UCL claims (which don’t offer monetary relief), plaintiffs must show that members of the public were likely to be deceived. The main liability question was misleadingness. Meta’s challenges to the merits didn’t make class treatment inappropriate; to the extent that merits scrutiny was warranted, plaintiffs showed that all class members were exposed to a similar representation about the ability of Potential Reach to reach “people,” namely unique individuals. And plaintiffs showed that Meta’s Potential Reach metric was not actually an estimate of people reached, but an estimate of “accounts” reached.

Meta argued that the Potential Reach numbers were not uniformly inaccurate as a result of different targeting criteria producing different Potential Reach numbers. “Even so, Potential Reach was always expressed as a number of ‘people,’ and the discrepancy between people and accounts made the number inaccurate, even if the numerical value of the inaccuracy varied across advertisers.” Whether Meta made misrepresentations to all class members was subject to common proof, as was Meta’s knowledge of the misleading statements, and intent to deceive. There were documents indicating Meta’s knowledge of the inaccuracy, and Meta also knew “that the potential reach number was the most important number in its ads creation interface and that advertisers frequently relied on the estimated audience to build their budgets and advertising strategies.”

Likwise for materiality and reliance. “[A] presumption, or at least an inference, of reliance arises wherever there is a showing that a misrepresentation was material,” and materiality “can be proved through evidence common to the class.” All advertisers in the class saw Potential Reach metrics, and a “majority” of advertisers rely on Potential Reach as a metric for their advertisements. Proof of injury was also susceptible to common proof. Plaintiffs’ expert concluded that it was a statistical certainty that, for any advertisement with a Potential Reach of at least 1,000 people or more, the estimate would be significantly inflated above the actual number of people the advertisement could reach, even though the amount of inflation might vary. Plaintiffs also offered experts who calculated a price premium, and the court declined to exclude plaintiff’s expert who performed a relevant conjoint analysis.

Superiority: obviously, since the price premium at issue here for each advertiser was no more than $32.

What about a Rule 23(b)(2) class for the UCL injunctive relief claim? Such a class may be certified when “the party opposing the class has acted or refused to act on grounds that apply generally to the class, so that final injunctive relief or corresponding declaratory relief is appropriate respecting the class as a whole.” Plaintiffs sought an order directing Meta to “either (a) correct the [Potential Reach] metric by removing known sources of inflation, or (b) remove the [Potential Reach] metric altogether.” They had standing to seek this remedy because “[k]nowledge that the advertisement or label was false in the past does not equate to knowledge that it will remain false in the future.” Plaintiffs testified that they would consider purchasing ads from Meta again if Meta corrected or removed the misleading Potential Reach metric. Meta argued that plaintiffs did not show they face a threat of actual future harm because at least one inflation source has already been remediated and Meta updated disclosures about multiple accounts. That was a merits question, as were Meta’s objections to the scope of the requested injunction so plaintiffs got a a Rule 23(b)(2) class for their UCL claims.


Monday, April 25, 2022

worsening child labor problem makes falsity of Nestle's socially responsible cocoa claims plausible

Walker v. Nestle USA, Inc., 2022 WL 901553, No. 3:19-cv-723-L-DEB (S.D. Cal. Mar. 28, 2022)

Walker alleged that Nestle’s product labels falsely lead consumers to believe that the products were produced in accordance with environmentally and socially responsible standards, including references to the “NESTLÉ® Cocoa Plan,” “UTZ” (a certifier), sustainable sourcing, and representations that Nestle supports cocoa farmers or helps improve their lives. E.g., “Supporting farmers for better chocolate. The NESTLÉ® Cocoa Plan works with UTZ to help improve the lives of cocoa farmers and the quality of their products.” In fact, Walker alleged, Nestle sources its cocoa from West African plantations which rely on child labor and child slave labor, contribute to deforestation, and use other practices harmful to the environment. According to Nestle’s own alleged statements, the child labor conditions have worsened rather than improved since the inception of the “NESTLÉ® Cocoa Plan”: from 2017 to 2019, the number of children working on cocoa farms nearly doubled.

Walker alleged CLRA and UCL violations.

The court found deception plausible:

The statements on Defendant’s products that the cocoa is “sustainably sourced” based on the “NESTLÉ® Cocoa Plan,” which is said to “help improve” the lives of farmers and “support” them, are at odds with the fact that the child labor problem the Nestlé Cocoa Plan is said to address has grown more, and not less, severe. The addition of the UTZ certification enhances the advertising statements by suggesting they are true because they were approved by a third party.

Article III standing: Walker alleged that she bought Nestle’s hot cocoa mix and morsels products, in reliance on the statements on product packaging, and wound not have purchased the products has she known that the statements were false. (She also alleged that she would like to purchase the products in the future “if and when they [are] produced as advertised[, but] can no longer rely on the accuracy of the representations ... in deciding whether to purchase these products, and ... cannot readily determine whether the misrepresentations have been corrected.” That was enough to allege Article III standing for herself and as a putative class representative. What other products could be covered in the class was a question for the class certification stage.

 

repeat purchase doesn't render consumer protection claim implausible

Harris v. Rust-Oleum Corp., 2022 WL 952743, No. 21-cv-01376 (N.D. Ill. Mar. 30, 2022)

Rust-Oleum sells RainBrella, “an inexpensive glass treatment for car windshields to help repel rain, mud, and dirt. RainBrella’s packaging includes statements that it ‘Lasts 2X Longer’ than a leading competitor and ‘Lasts Over 100 Car Washes.’” Building on a previous Lanham Act case in which Rust-Oleum was found liable for false advertising, but only the “Lasts 2X Longer” liability survived an appeal, Harris sued under Wisconsin’s consumer protection law and the court kicked out the class action claims, but not her individual claims.

Wisconsin’s Deceptive Trade Practice Act: She sufficiently alleged reliance by alleging that RainBrella prominently displayed statements on its packages, which she bought; that those statements were false; and that, had she known they were not true, she would not have purchased the product. She admittedly purchased the product numerous times over three years, but

that Harris apparently believed RainBrella worked well enough to keep purchasing is not dispositive of the question at issue here, at least with regards to the claim that it “Lasts 2X Longer” than the leading competitor. Harris may have been satisfied enough with RainBrella not to seek out a competing product, but she also may have done so with the belief that RainBrella did indeed, as it stated, “Last 2X Longer” than any other option.


two opinions send "false advertising of certification mark" claim to jury

U.S. Structural Plywood Integrity Coalition v. PFS Corp., 2022 WL 898598, No. 19-62225-CIV-ALTMAN (S.D. Fla. Mar. 28, 2022)

Take it away, Judge Altman:

If you want to build with plywood in the United States, you generally need a certification— called a PS 1-09 stamp. The Plaintiffs are a coalition of ten American structural-plywood mills who manufacture and sell their plywood in the United States. The Defendants are two companies that inspect structural plywood and, if it conforms to the PS 1-09 standard, stamp the wood as PS 1-09-compliant. According to the Plaintiffs, the Defendants have been certifying 36 Brazilian plywood mills with the PS 1-09 stamp—even though the Defendants know (or should know) that the Brazilian wood doesn’t comply with the PS 1-09 standard. In the Plaintiffs’ view, this sham certification process has allowed the Brazilian mills to sell their cheaper, non-compliant wood all over the United States—thus displacing the Plaintiffs’ stronger, better, more expensive products. In their complaint, the Plaintiffs levy negligence and Lanham Act claims, which the Defendants have now moved to dismiss.

The court denied the motion.

The plaintiffs alleged that the stamps themselves were “a powerful form of advertising because they allow the Brazilian plywood companies to market their products as conforming to an important American safety standard.” They alleged that faster-growing Brazilian trees can’t conform to the standards and suffered “shocking” failure rates, but that imports of these lower-priced products pushed down the price of structural plywood across the United States.

pictures of not-good plywood from case

Plaintiffs alleged both direct and contributory false advertising.

Defendants challenged whether plaintiffs identified any false or misleading statements by defendants.  In Baldino’s Lock & Key Serv., Inc. v. Google, Inc., 624 F. App’x 81 (4th Cir. 2015), the court dismissed a false-advertising claim against Google for knowingly publishing the ads of unlicensed locksmiths because “the locksmiths who generated the information that appeared on [Google’s] websites [were] solely responsible for making any faulty or misleading representations or descriptions of fact.” But here, defendants did make representations about the quality of the Brazilian products. They gave the Brazilian mills the authority to certify their plywood with the Defendants’ PS 1-09 stamps, which “serve as a proxy for the Defendants’ view that the Brazilian mills comply with the PS 1-09 standard” and which were required for the plywood to be legal to sell in the US.

Example of stamps at issue

If Google is like an office building that leases space to businesses, including doctors, defendants were like the state medical licensing board. Leasing space doesn’t make any kind of statement about licensure, but the licensing board, by issuing licenses, “is making a powerful statement—some would say, the most important statement—about the doctors’ qualifications.” If Google is like a highway, no one would say that allowing cars onto the highway certifies that they’re licensed drivers—but the DMV does certify that a driver is qualified, just like the defendants’ stamps certify that the Brazilian plywood mills have satisfied the PS 1-09 standard.

Defendants denied making any statements at all, since in their view it was the Brazilian companies that made and stamped the wood, and who were really speaking. “But the Brazilian plywood companies didn’t steal or forge the Defendants’ stamp. The Defendants gave them the stamp and authorized them to use it. Indeed, these stamps bear the Defendants’ names and advertise the plywood as either ‘[defendant] TESTED’ or ‘AUDITED BY [defendant].’ These stamps are thus unquestionably statements of the Defendants.” The medical board’s license is its statement even if the doctor is the one who frames it and displays it on their wall. The argument was also nonsensical outside this litigation: “Imagine the uproar when the Brazilian mills’ clients learn that the certifications they’d come to rely on—for safety, quality, etc.—weren’t the Defendants’ certifications at all.… What value, in other words, would the certification hold if it were just the self-affixed manifestation of any-old mill’s efforts at self-policing?”

Even if the stamps weren’t “statements,” plaintiffs also alleged that defendants made other false statements, such as in responding to a report about the massive failure rates of Brazilian plywood with reassurances in letters to clients. E.g., “Panels certified by Timber Products Inspection are equivalent to those certified by other accredited agencies. This letter can be shared with clients, sales groups, inspectors, or others that are in need of this information.”

Contributory false advertising: Plaintiffs also sufficiently alleged that defendants “contributed to [false advertising] either by knowingly inducing, or causing the conduct, or by materially participating in it.” Because it was undisputed that the Brazilian mills couldn’t sell their structural-plywood in the United States without the defendants’ stamp, the alleged “looking the other way” “easily satisfies” the “material participation” standard, and plaintiffs also alleged knowing conduct.

Commercial advertising or promotion: Defendants argued that because they didn’t stamp the plywood themselves or profit directly from the plywood’s sale, the stamps weren’t commercial advertising.

 But “commercial speech encompasses not merely direct invitations to trade, but also communications designed to advance business interests.” And even if defendants didn’t apply the stamps themselves, the stamps unquestionably “advance” their “business interests,” since their entire certification business depended on the message the stamps conveyed.

The more plywood the mills sell, the more money the Defendants make. Conversely, if the Brazilian mills were to go out of business, the Defendants would make a lot less money (or, perhaps, go out of business themselves). Since the stamps are the principal mechanism by which this whole circle of life flourishes, the Plaintiffs have adequately pled that the stamps constitute the Defendants’ “commercial advertising.”

Nor were the stamps mere statements of opinion. Other cases involving “ratings” deemed opinion didn’t involve “a series of engineering tests susceptible of objective examination,” but rather “subjective assessments by third-party entities that had no control over market entrants.” This was the difference between the medical licensing board and a third-party evaluator using public data to score doctors, whose ratings can only be opinion. (James Grimmelmann has an excellent paper on ratings as facts, opinions, and self-fulfilling prophecies that prefigures the reasoning here.) The licensing board that certifies “isn’t offering an opinion at all: it’s attesting that the aspirant has (objectively) passed its tests, met its standards, or satisfied its prerequisites.” The certifier might be wrong—which is what defendants might have been getting at when they pointed out that certification was inherently based on sampling and was complex—but “the possibility that the certifier might get the tests wrong—or apply the tests improperly—doesn’t somehow render the tests subjective. We can all agree that the answers to questions of math are objective, even if, from time to time, a young student may erroneously believe that two and two is five.”

Plus, plaintiffs weren’t merely alleging that the Brazilian plywood failed to meet the PS 1-09 standards. “They’re also saying that, by stamping the wood, the Defendants certified that they had subjected the mills to certain quality-control processes—even though, the Plaintiffs assert, they did no such thing.” And that’s not opinion: “Either the Defendants tested the wood—or subjected it to quality-control review—or they didn’t.”

Proximate cause: Defendants argued that their certification of the Brazilian mills was not the proximate cause of the plaintiffs’ injuries. But Lexmark allows for proximate cause even without diversion of sales to a direct competitor. As in Lexmark, plaintiffs alleged that deception of consumers caused those consumers to withhold trade from them, given that Brazilian plywood is cheaper to produce—allegedly in large part because of a lack of compliance with PS 1-09. Again, without defendants’ certification, the Brazilian mills couldn’t sell their plywood in the United States, at least not for structural purposes. That’s enough for proximate cause.

Plaintiffs also successfully alleged negligence under Florida law.

 

U.S. Structural Plywood Integrity Coalition v. PFS Corp., 2022 WL 953150, No. 19-62225-CIV-ALTMAN (S.D. Fla. Mar. 30, 2022)

Summary judgment ruling (I guess the motion to dismiss opinion was in his pocket for a while?).

Some additional info: Defendant PFS-TECO argued that the PS 1 Standard gave it discretion in deciding how to inspect and certify, and allowed the processes attacked by the plaintiffs: granting interim approvals, relying on subcontractors to visit Brazilian mills, and allowing Brazilian mills to select for themselves the small sample of product that will be tested. Even so, some of the plywood it received “seemed plainly non-compliant—to the point where one could, for example, ‘break the veneers off with [a] hand[.]’” The court showed some pictures of plywood that did not look structurally sound.

The parties offered competing experts on whether defendants complied with the standard and whether the certified plywood was any good.

Defendants’ arguments for summary judgment:

Lanham Act standing: The court found sufficient evidence of proximate cause to go to the jury. Plaintiffs’ economic expert “established a close correlation between the influx of Brazilian structural plywood into the U.S. market, the concomitant decrease in the price for structural plywood in the United States, and a concurrent decline in the Plaintiffs’ annual sales.” That, standing alone, was probably enough to withstand summary judgment. The expert’s regression model took other independent variables into account; a jury wouldn’t have to believe him, but could. There was also testimony from structural plywood sellers about declining sales corresponding to Brazilian supplies in the market. Although they couldn’t identify specific consumers who had stopped purchasing U.S. plywood in favor of cheaper Brazilian imports, they had relevant knowledge and understanding of how price influenced market outcomes. “Like most businessmen, they don’t need to sit down with individual customers to uncover their own (frightening) reality. And they certainly don’t have to run consumer surveys before they can tell us—and, one day, a jury—about their observations.” Maybe they were mistaken, or biased, but that was a credibility issue for the jury. To get past summary judgment, plaintiffs didn’t have to provide complaints about the Brazilian plywood’s real-world failure rate (though defendants’ own documents apparently showed some) or identify specific customers who opted not to buy plaintiffs’ product on cost grounds. The court noted that defendants’ emails included open discussion of failure rates of Brazilian plywood and of whether they should talk to the mill owners about that, though they often blamed shoddy construction at least in part for the problems.

There was also a genuine issue of whether the TECO TESTED® stamp communicates something about the plaintiffs’ own product, e.g., defendant PFS-TECO claimed that “Panels with the TECO TESTED® certification mark are interchangeable with panels marked by other certification agencies.” They weren’t required to mention plaintiffs by name.

Plaintiffs also created a fact issue on literal falsity about whether Brazilian licensees’ plywood met the PS 1 standard, based on various studies. And the standard itself could be read to suggest that monitoring was required; there was also evidence that “PFS-TECO may not be monitoring its Brazilian mills properly.” Although plaintiffs’ tests didn’t test every part of the standard, they tested the key feature—bending stiffness/strength—and concluded that the Brazilian plywood couldn’t pass that, so the fact that they didn’t do a full evaluation wasn’t dispositive.As one expert succinctly explained: “When you qualify the product, every test [is] a minimum requirement. If there is one test fail, that whole qualification fail.”

A jury could go either way on whether defendants complied with the relevant standard, which says in relevant part: “Plywood represented as being in conformance with this Standard shall bear the stamp of a qualified inspection and testing agency which … inspects the manufacture (with adequate sampling, testing of the bond line, and examination of quality of all veneers).” Plaintiffs provided sufficient evidence for a jury to find that the inspection was inadequate, and in any event, they provided sufficient evidence that the plywood itself was inadequate. A reasonable jury could certainly decide that the stamps provided assurance of conformity to the standard, even if the stamps don’t and really can’t indicate that every individual panel conformed. There was testimony that 95% of panels should comply, and evidence that Brazilian plywood failed at far higher rates.

Sure, the studies tested plywood from only 7 of 14 Brazilian clients. But their wood expert specifically testified that the deficiencies were endemic to the region and affected the growth of southern yellow pine throughout.

Materiality: Again, more than enough evidence to go to a jury. Among other things, PFS-TECO’s own internal and external communications so indicated, e.g., “when builders, code officials, and others in the building design and construction communities see the PFS Checkmark or TECO TESTED® designations …, they know that the products meet PFS TECO’s performance requirements and those of the particular standard to which they are certified ….” No survey or direct customer testimony is required.

Contributory liability: PFS TECO argued that there was no evidence that it induced or knowingly or intentionally participated in any of the allegedly false statements made by the Brazilian mills, other than having a licensing agreement with them. But there was plenty of evidence that it knew about the allegedly shoddy product, including employee emails. And there was enough evidence for a jury to find that PFS-TECO “materially furthered the unlawful conduct—either by inducing it, causing it, or in some way working to bring it about.” For example, defendant’s own expert testified that PFS-TECO didn’t retain any data on whether (and to what extent) its clients meet the Standard, despite knowing that much of the Brazilian plywood did not meet that Standard. It allowed mills to self-select what would be tested, and apparently allowed them to re-test to improve failure rates and even agreed to “forego the full qualification testing” in one instance. In combination with the “extraordinary” failure rates shown in plaintiffs’ studies, this was “compelling” evidence of three important contributory liability considerations: “the nature and extent of the communication between the third party and the defendant regarding the false advertising; whether or not the defendant explicitly or implicitly encouraged the false advertising; [and] whether the false advertising is serious and widespread, making it more likely that the defendant knew about and condoned the acts[.]”

And plaintiffs’ lost profits claims were backed by evidence sufficient to get to a factfinder. Reasonable probability, not absolute certainty, is the standard. Plaintiffs’ expert’s regression analysis was a well-recognized, valid approach, and concluded that the influx of Brazilian plywood has caused significant declines in the price of U.S. plywood.

Negligence: whether defendants owed a duty to plaintiffs is a question of law, not a jury question. The court previously concluded that defendants’ “alleged failure to perform the core responsibilities of testing, inspecting, and certifying a structural product creates a general and foreseeable risk of harm,” including physical injuries as well as economic injuries to domestic manufacturers. A reasonable jury could find the other elements of negligence present.

Finally the court rejected the argument that a court shouldn’t decide whether the defendant complied with the Standard, because that would make the Standard no longer voluntary. But there’s no standards authority exhaustion requirement in the Lanham Act.


Noncommercial speakers can be liable for contributory false advertising

ExeGi Pharma, LLC v. Pacifici, 2022 WL 889275, No. 1:21-CV-2134-TWT (N.D. Ga. Mar. 25, 2022)

I know it probably seems sometimes like I approve of every expansive use of false advertising law, but sometimes even I find an aggressive position to go too far. Here, ExeGi sues a doctor for producing some of the materials ExeGi’s rivals use to promote themselves, and the court approves a contributory false advertising claim, reasoning that the “commercial advertising and promotion” requirement applies only to the underlying speech, not to the doctor’s speech. That seems doctrinally correct but not quite the point: The real question ought to be whether the imposition of liability on the doctor’s noncommercial speech satisfies strict scrutiny. Maybe it does, but I have doubts. Also, we really need a federal anti-SLAPP law.

As with other ExeGi cases, the core is “competing probiotic products used to treat certain gastrointestinal diseases.” De Simone created an eight-strain combination probiotic product known as the De Simone Formulation. This was first used by VSL, marketed as VSL#3. De Simone then split from VSL, which eventually lost the license for the De Simone Formulation and attempted to reverse engineer it/replace it. After a trial, VSL was barred from advertising its new formulation as the same as the De Simone Formulation and from relying on studies performed on the De Simone Formulation.

Defendant Pacifici “is a professor at Emory University who has been studying the clinical application of probiotics since at least 2012.” He conducted a study on the De Simone Formulation’s effect on bone loss of mice during menopause. He became an advisor to VSL after the split from De Simone, and gave a presentation in Italy where he allegedly presented data from studies performed on the De Simone Formulation as if the data represented analysis of the Italian Formulation.

He also, allegedly at VSL’s request, joined a “GRAS Panel” regarding the Italian Formulation with two other professors and ultimately signed a report on it, which ExeGi alleged was “fatally flawed” by its reliance on studies performed on the De Simone Formulation. The report concluded that the Italian formulation qualifies both as “GRAS” and as a “medical food” under US law, allegedly giving credence to these claims. [I want to pause for a moment and consider how this would go as a consumer protection lawsuit, where courts are often totally happy to allow marketing claims based on studies vaguely in the area of the defendant’s ingredients.] Anyway, ExeGi sued for contributory false advertising/unfair competition under the Lanham Act, a violation of Georgia’s unfair competition statute, and tortious interference.

The Eleventh Circuit allows contributory false advertising claims where there is direct false advertising and the defendant contributed to that conduct either by knowingly inducing or causing the conduct, or by materially participating in it. Liability requires “that the defendant had the necessary state of mind—in other words that it ‘intended to participate in’ or ‘actually knew about’ the false advertising.” It is enough if a defendant provides “a necessary product or service, without which the false advertising would not be possible.”

The court found that claim preclusion didn’t apply and that the FDCA did not preclude the Lanham Act claims. Defendant argued that the Lanham Act claims here would require the Court “to interpret and apply a complex web of statutory and regulatory provisions about the requirements for a ‘medical food’ and ‘GRAS’ substances.” Even though ExeGi argued that it wasn’t making a “technical” argument but just that the designations were “claimed fraudulently and wholly unsupported,” the court cut to the heart of the claim and held that, even accepting the allegations as true, using data from the De Simone Formulation didn’t mean that the Italian Formulation was neither “medical food” nor “GRAS.” Those things depended on whether the proper tests had been performed, and “[t]his scientific inquiry is decidedly one left to the exclusive jurisdiction of the FDA under the FDCA.”

However, the contributory false advertising claim also was based on defendant’s claim that the two formulations were equivalent, which was not precluded.

ExeGi sufficiently alleged primary false advertising, and that the GRAS Report signed by Pacifici serves as the “underpinning of much of the false advertising engaged in” by the primary defendants. It was plausible that Pacifici’s signature on the report and decision not to withdraw that signature constituted participation in the alleged false advertising. The Eleventh Circuit has held:

It is also conceivable that there could be circumstances under which the provision of a necessary product or service, without which the false advertising would not be possible, could support a theory of contributory liability. In determining whether a plaintiff has adequately alleged facts to support such a claim, we look to whether the complaint suggests a plausible inference of knowing or intentional participation, examining the nature and extent of the communication between the third party and the defendant regarding the false advertising; whether or not the defendant explicitly or implicitly encouraged the false advertising; whether the false advertising is serious and widespread, making it more likely that the defendant knew about and condoned the acts; and whether the defendant engaged in bad faith refusal to exercise a clear contractual power to halt the false advertising.

Here, ExeGi alleged “that the GRAS Report materially supported a third party’s false advertising, that Pacifici knew of the alleged false equivalence being expressed in the Report, that he was informed by De Simone and an attorney for a rival company that these statements indicated equivalence between the formulations, and that he refused to rescind his signature after being presented with this information.” That was enough here.

ExeGi was not required to allege that Pacifici’s speech was commercial, because that’s only a requirement for the primary false advertising.

§43(a)(1)(A) unfair competition: ExeGi alleged that Pacifici’s continued authorization of the GRAS Report causes confusion as to whether the Italian Formulation’s is certified as GRAS and a medical food, whether the medical community has a consensus view that the Italian formation is safe for its intended use, and that the Italian Formulation “is of a particular standard and quality.” But ExeGi failed to allege that the GRAS report caused confusion about equivalence, and the rest of this was precluded by the FDCA, so it was kicked out. (Also, using §43(a)(1)(A) as a cut-rate false advertising claim does pose some First Amendment problems, but the court doesn’t say anything about that!)

Georgia’s Uniform Deceptive Trade Practices Act creates a cause of action against a person who, “in the course of his business, vocation, or occupation, [r]epresents that goods or services are of a particular standard, quality, or grade or goods that are of a particular style or model, if they are another[.]” Defendant didn’t sufficiently brief preemption, as opposed to preclusion, but the UDTPA does not apply to “[c]onduct in compliance with ... a statute administered by a federal, state, or local governmental agency[.]” Because the FDCA gives the FDA the ability to monitor and enforce false claims of GRAS or medical food designations, the UDTPA didn’t apply.

Tortious interference: This requires an allegation “that the defendant directly induced adverse behavior by the third party.” But ExeGi failed to allege that customers read the GRAS Report or made their purchasing decisions on that basis, and instead explicitly alleged that it led to false advertising that then induced others to act.

Thursday, April 21, 2022

Art kerfuffle of the day

 Stuart Semple has a well-publicized, highly entertaining feud with Anish Kapoor. According to the email I received, 

KAPOOR HAS FINALLY UNVELIED WHAT HE'S BEEN DOING WITH VANATABLACK THIS WHOLE TIME



AND IT'S NOTHING BIG OR CLEVER!

Hi Rebecca

I always knew this day would come. A day where finally Anish Kapoor would show us all what he needed the exclusive rights over Vantablack for. 

After years and years in the making...

Little did I expect I'd wake up to mainstream newspapers trying to provoke another chapter of the art war, to promote his art show at the Venice Biennale. 

Does his work above look familiar? 

THAT'S PROBABLY BECAUSE IT'S ALMOST IDENTICAL TO THIS PIECE I MADE WITH OUR BLACK 3.0 A FEW MONTHS AGO!

... Anyway, Semple is offering his own Biennale in a Box:

I've made a replica of his work, that he's unveiling at the Biennale. I want *everyone to be able to have it if they like, because art should be for everyone!

*usual exclusions apply

My note: I love that his asterisk refers to the "usual exclusions," which constitute his quite unusual exclusions for Kapoor and anyone associated with him.

Wednesday, April 20, 2022

Reading List: Democracy of Sound

 Insta-rec for Alex Cummings, Democracy of Sound: Music Piracy and the Remaking of American Copyright in the Twentieth Century. Electronic access may be available through your institution. Well-written narrative of copyright law from the perspective of (1) recorded sound and in particular (2) how people who made copies of records shaped legal reactions thereto. A few bobbles ("Justice" Learned Hand; the description of the DMCA could have been improved), but does a great job contextualizing music copyright in larger political, social, and legal currents. Cummings provides a particularly clear explanation of why copyright in sound recordings seemed inappropriate early on, when everyone assumed that recordings would mostly be of lectures--it didn't make much sense to say that one version of a stump speech would have a separate copyright from another, or that a record company could own a copyright in a professor's lecture that would seemingly stop him (always him) from delivering the lecture to some other audience. And after the initial attempt to get federal sound recording copyright failed, attention shifted to the states. If you remember how Viacom accidentally accused some of its own YouTube channels of piracy, you may also see that prefigured in how RCA ended up pressing discs of copies of its own recordings on behalf of an outfit literally named Jolly Roger.

Friday, April 08, 2022

Reading list: The Hydraulics of Intermediary Liability Regulation

My former student Ben Horton has published The Hydraulics of Intermediary Liability Regulation, 70 Clev. St. L. Rev. 201 (2022), making an important point about the tradeoff between exposing platforms to greater liability for unlawful content and their ability/incentives to remove "lawful but awful" content. Recommended!

 Abstract:

The intermediary immunity created by Section 230 probably protects claims based on the non-legal harms of hate speech and misinformation as well as a European-style proportionality system of content moderation better than a more “legalized” intermediary liability regime would. Contrasting the existing non-copyright content moderation systems with empirical research on the effects of the Digital Millennium Copyright Act (DMCA) shows that a comprehensive regulation of content moderation would incentivize the moderation of defamation and negligence claims at the expense of these important non-legal claims and incentivize a homogenous, categorical approach to content moderation. Furthermore, empirical research on the effects of SESTA-FOSTA and online secondary copyright liability outside the DMCA’s safe harbor shows the effects of a non-comprehensive solution would be even worse: incentivizing widespread automation and crude blocking with negligible positive effects. Instead, policymakers should focus on narrow changes to Section 230, remedies that punish systemic violations, and non-tort solutions. 


Friday, March 25, 2022

Asterisk can't limit "reef safe" sunscreen claim to only 2 ingredients

Locklin v. StriVectin Operating Co., 2022 WL 867248, No. 21-cv-07967-VC (N.D. Cal. Mar. 23, 2022)

StriVectin makes sunscreen products that it labels “REEF SAFE* SUNSCREEN.” Fine print says that the product does not contain two particular ingredients that are widely thought to harm coral reefs. But plaintiff successfully alleged that the sunscreen contains four other ingredients that endanger the reefs (avobenzone, homosalate, octisalate, and octocrylene) and that the label is therefore misleading.

The complaint alleged that specific facts about the four chemicals were supported by studies, e.g., that octocrylene “has been shown to accumulate in various types of aquatic life” and “adversely impacts coral reefs, even at low concentrations, by accumulating in coral tissue and triggering mitochondrial dysfunction.” A graphic from the National Oceanic and Atmospheric Administration that describes how sunscreen washes off human skin and wreaks havoc on marine life, including coral lists octocrylene as an ingredient “that can harm marine life.” The U.S. Virgin Islands has banned octocrylene, and the Republic of the Marshall Islands has banned avobenzone. Palau recently enacted a nationwide ban on sunscreens containing any one of numerous ingredients, including octocrylene. And a bill in Hawaii would ban both of those.

StriVectin argued that the asterisk and back-package explanation sufficed to avoid misleadingness, because it had sufficiently defined “reef safe” narrowly to mean “does not contain two particular chemicals that harm coral reefs.”

The court thought this was “absurd.” While

asterisks might cabin sweeping claims or further define ambiguous language, … a company can’t say something misleading on the front of a label and escape liability by stating “that’s not actually what we mean” in fine print on the back. Imagine a product labeled “VEGAN*” on the front that contained chicken meat. The producer could seek no shelter by explaining on the back that “vegan” in this context means “contains no beef.” Or imagine a product labeled “SAFE* FOR HUMAN CONSUMPTION” on the front, with a caveat on the back stating that it “contains no cyanide.” If the product contained a lethal dose of ricin, the label would obviously mislead. StriVectin does not have free rein to define “reef safe” to mean anything it wants.

Here, the allegations indicated that StriVectin made a “promise” on the front that it “retracted” on the back.

Whether the studies cited proved reef endangerment wasn’t at issue at this stage. “Indeed, the complaint would plausibly allege that the chemicals harm the reefs even if it had cited to no study—because the body of the complaint ‘detail[s] the specific ingredients’ and how they threaten reefs, it does enough at this stage to state a claim.” In fact, “even if the chemicals pose only a serious—but ultimately uncertain—threat to coral reefs, that may well be enough to prove that the company’s ‘reef safe’ claim is false or misleading to a reasonable consumer who cares about avoiding using products that endanger the reefs.” Also, these weren’t lack of substantiation claims. The complaint identified “specific facts pointing to actual falsehood.”

And  Locklin had standing to pursue injunctive relief becaues he alleged that he would purchase StriVectin’s sunscreen again were the “reef safe” claim true.  

Thursday, March 24, 2022

Museums and moral rights

Hermon Atkins McNeil, The Sun Vow (at the NY Metropolitan Museum of Art):

Note the card displayed below--on the left, in black on white: "By the 1890s, sculptural representations of Native American and western themes had become extremely popular. While living in Chicago in the early 1890s, MacNeil had learned of a rite of passage that captured his imagination: before a boy on the threshold of manhood could be accepted as a warrior, he was required to shoot an arrow directly into the sun. If the chieftain judging the boy's prowess was so blinded by the sun's rays that he could not follow the flight of the arrow, it was said to have gone 'out of sight,' and the youth had passed the test. MacNeil portrayed the dramatic moment following the arrow's release, heightening both the visual impact of the composition and the sense of narrative suspense."

On the right, in white on black: "How will MacNeil's story end? The figures are suspended, held captive by a vow that the artist later admitted he perhaps made up. This representation of the futility of Indian action fosters a belief in their aimlessness. Where will the arrow land? It cannot. Ineffective and undirected, it must disappear. This reinforces a limited vision of Native success in which the youth, the next generation, must move beyond the blinded elder. In a celebration of naivety, the child smiles slightly at the release of the powerless arrow, contributing to the acknowledgement of landless future generations--of Natives forcibly separated from their territories, and from themselves. This depiction participates in a ritual of blindness to a civilizing violence understood as necessary.--Jackson Polys (Tlingit)"


Implied falsity and infant formula

Evolve Biosystems, Inc. v. Abbott Labs., 2022 WL 846900, No. 19 C 5859 (N.D. Ill. Mar. 22, 2022)

Evolve (and the Regents of the UC) sued Abbott for patent infringement related to an infant formula product; Abbott counterclaimed for false advertising under the Lanham Act and unfair competition under Illinois and California state law. “Evolve countered with its own counterclaims under these same laws. Specifically, Evolve alleges that Abbott made false and misleading advertising statements about Abbott’s competing Similac Probiotic Tri-Blend product.” The court denied Abbott’s motion to dismiss.

Evolve sells a Bifidobacterium longum subsp. infantis (“B. infantis”) probiotic product for preterm infants called EVIVO. “Research indicates that EVIVO, in combination with human milk oligosaccharide prebiotics, promotes B. infantis colonization in the infant gut, improving patient outcomes. Evolve’s EVIVO product is used in newborn intensive care units (“NICUs”) across the country.”

“[R]umors began to emerge that Abbott was preparing to launch a B. infantis product that would compete with EVIVO,” allegedly causing Evolve to lose business. And Abbott allegedly did intend to launch directly competing a B. infantis product—called Similac Probiotic Tri-Blend. It prepared marketing materials for Tri-Blend and listed it for sale on Abbott’s website. Evolve allegedly continued to lose business from potential customers who paused discussions with Evolve to wait for Tri-Blend’s imminent release.

Evolve’s EVIVO product utilizes a particular strain of B. infantis, which is allegedly better than other species/strains and can “grow more robustly in an infant’s gut,” which then can improve patient outcomes. Evolve alleges that using its products “significantly reduced necrotizing enterocolitis ... compared to cohorts receiving no probiotics” and “significantly reduced late onset sepsis ... compared to those receiving the probiotics bacterium L. reuteri and those receiving no probiotics.” Tri-Blend allegedly uses a different B. infantis strain rendering it less effective such that it “may not survive well in the infant gut.”

Abbott advertised that Tri-Blend has “potency” and “stability” and is composed of “high-quality probiotic strains,” while allegedly being aware that B. infantis is more important than other probiotics and that the strain in Abbott’s product is not as effective as the strain in Evolve’s product. Abbott also states that Tri-Blend is a “unique blend,” and its marketing materials and advertisements proclaim that multi-strain probiotics “have functional advantages over single strain probiotics.” Abbott instructed its sales representatives to convey that message to customers in order to distinguish between Tri-Blend and competing products like Evolve’s EVIVO. Abbott allegedly intended to suggest to consumers that the BB-02 B. infantis strain comprises one-third of the colony-forming units in the Tri-Blend product, but it hasn’t verified that.

Rule 9(b): Evolve sufficiently pled the who, where, what, and how. “Abbott is correct that Evolve has not pleaded exact times and exact locations, that is when and where the challenged statements or labels were delivered to ‘hospitals and NICUs.’ Yet, Rule 9(b)’s particularity standard requires ‘flexibility when information lies outside of [the] plaintiff’s control.’ And as between the parties, it is Abbott that knows the exact times and dates of its sales pitches and product deliveries to its customers in this case. Therefore, Evolve’s pleading satisfies Rule 9(b).”

Puffery: Were “statements that Tri-Blend is a ‘unique blend’ with ‘high-quality probiotic strains,’ exhibits ‘potency & stability,’ and has ‘functional advantages over single strain probiotics’ ” actionable? First, statements are not puffery if they can be tested—if they make “objective claims” that describe “specific or absolute characteristics of a product capable of testing.” “Second, commercial statements are not puffery if reasonable consumers could rely on them in their purchasing decisions—if they are ‘specific’ enough to induce ‘consumer reliance.’” Evolve alleged that the physical characteristics of the strains causing them to differ were measurable, as were the strains’ clinical effects on preterm infants. It was reasonable to infer that probiotic viability in manufacture and transport was also measurable, and that potential consumers—here, hospitals and their NICUs—are aware that infant probiotic products can be tested for function and efficacy. Thus, it was reasonable to infer that customers of infant probiotic products rely on such commercial language as “poten[t],” “stabl[e],” and “high-quality” to denote the products’ function and efficacy. So too with statements that Tri-Blend is a “unique blend” with “functional advantages over single strain probiotics,” which “invokes a testable comparison between single-strain and multi-strain probiotics.” Abbott’s own exhibits specifically cited a scientific study to support the statements that Abbott’s Tri-Blend product is a “unique blend” and that multi-strain probiotics “may have functional advantages over single strains.” Another stated that Abbott’s product has been subjected to “controlled, rigorous testing,” that its “product potency & stability [is] ensured,” and that the product was “tested.”  Consumers could reasonably treat these as statements of fact.  Nor was the use of the word “may” in “may have functional advantages over single strain probiotics” protection against misleadingness, since Evolve was entitled to present evidence of actual consumer understanding.

What about the allegedly implied misrepresentation that infantis BB-02 accounted for 1/3 of the product? Abbott argued that its label wasn’t “commercial advertising or promotion.” But that phrase means nothing more than “promotional material disseminated to anonymous recipients.” The label was that. It was plausible that describing the product as a “blend” of three ingredients implicitly conveys to consumers the message that those three ingredients are present in equal parts.

Wednesday, March 23, 2022

SmileDirect may indirectly deceive: "implicit misrepresentation of FDA approval" theory is not precluded

Ciccio v. SmileDirectClub, LLC, 2022 WL 843774, No. 3:19-cv-00845 (M.D. Tenn. Mar. 21, 2022)

The district court doesn’t seem to be having much fun with this case, but issues a thorough and thoughtful opinion that highlights a big conflict in false advertising law—not a split, but a conflict about when courts will consider implicit falsity/misleadingness, the other side of which was represented by last week’s Bimbo Bakeries decision.

Roughly: Orthodontists accused SDC of falsely advertising its plastic aligners as equivalent to traditional orthodontic treatment. Here, SDC sought to narrow the scope of bitterly-fought discovery by getting rid of any claims based, in whole or in part, on allegations that SmileDirect improperly marketed itself as in compliance with federal regulations governing dental devices. The plaintiffs alleged that “[a]t no time has SmileDirect informed consumers that it is in violation of the [Food, Drugs, and Cosmetics Act (‘FDCA’)] and illegally practicing dentistry” and that “[b]oth of these nondisclosures are highly material and highly fraudulent because consumers would be reluctant to use SmileDirect’s aligners in any capacity if they knew that they were being sold in violation of both federal and state law.” Plaintiffs alleged that, “[a]s a manufacturer of its aligners, SmileDirect was legally obligated to seek FDA clearance for such product,” but that it has instead opted to “flout these legal requirements and is selling its product, which should be labeled and sold only by prescription, in an essentially over-the-counter fashion.”

SDC argued that the court should dismiss any such claims because “only the Food and Drug Administration can enforce the FDCA.”  [Procedural discussion, and discussion of an related Tennessee Consumer Protection Act issue, omitted.]

POM Wonderful LLC v. Coca-Cola Co., 573 U.S. 102 (2014), would seem to support plaintiffs’ arguments that they could enforce the Lanham Act even against FDA-regulated activity. SDC distinguished Pom Wonderful by noting that here, the allegations are about FDA approval. Nonetheless, the allegations were not trying “to police or otherwise interfere with SmileDirect’s dealings with the FDA, nor are they trying to enforce any provision of the FDCA in the FDA’s stead.” Instead, they were arguing that SDC’s marketing misled consumers about its FDA clearance status. (Citing JHP Pharms., LLC v. Hospira, Inc., 52 F. Supp. 3d 992, 1000 (C.D. Cal. 2014) (“[I]f a product has been approved [by the FDA], consumers may take some assurance that it ... meets the agency’s ... standards. This makes an FDA-approved product a more attractive product ....”) The plaintiffs were not alleging that SDC’s disclosures/nondisclosures violated the FDCA, or that there was a general duty to disclose FDA clearance/approval status. Rather, they argued that SDC’s “particular marketing strategy and materials, in the unique context of the orthodontic industry and the particular consumer expectations predominant in that industry, were misleading in a way that could have been, but was not, rectified by such a disclosure.” This was ok, same as in Pom Wonderful: “the Lanham Act applies to this industry just like any other, and ‘[n]othing in the text, history, or structure of the FDCA’ suggests a carve-out for this particular type of unfair competitive practice.”

The defendants even conceded that a false affirmative claim of FDA approval could be subject to the Lanham Act. But they argued that preclusion applied to a theory that the ads falsely implied FDA approval/clearance. The court previously concluded that plaintiffs sufficiently pled “that the defendants misleadingly characterized their products and services as equivalent to traditional orthodontic treatment.” Although plaintiffs didn’t identify specific affirmative claims that SDC’s aligners were FDA-cleared or -approved, they did make a lot of braces-equivalence claims, and the plaintiffs’ theory was that, “in the context of orthodontic care, a reasonable consumer would read SmileDirect’s assertions of equivalence to traditional orthodontic treatment to suggest that such approval or clearance occurred. Whether that is actually true is a factual question ….”

The court rejected SDC’s proposed explicit/implicit division on FDA-related claims as making “little sense.” “The possibility that a consumer can be misled by omission and/or implication is both factually undeniable and well-recognized by the law. Why, then, would that type of well-recognized claim be precluded, if a substantively equivalent claim based on an affirmative statement would not?” The court also noted “substantial practical challenges to applying such a rule,” since “every misrepresentation involves an omission of the true information,” and a plaintiff may, “ ‘[t]hrough word games, ... style his or her complaint as a material misrepresentations [case] or [an] omissions case’ without any change in the substance. Treating one type of claim as wholly precluded and the other as permissible would cause the viability of a plaintiff’s claim to hinge on distinctions too malleable to be safely relied upon, at least in borderline cases.”

So too with allegedly implied claims of dental licensure.

Comment: I am completely aligned (so to speak) with the court here. But it has to be said that Mead Johnson/Bimbo Bakeries analysis is in conflict—not a split, because the same courts that have adopted Mead Johnson say that they accept that implied falsehoods are actionable; they just won’t tell you in advance which ones—because Mead Johnson says that courts are not allowed to recognize some false implications even when shown to exist via empirical evidence. Honestly, preclusion is a better reason than most of those cases have given. Would confining liability only to explicitly false claims avoid some chilling effects? Sure! That’s why it’s a useful test in Rogers v. Grimaldi. But Rogers is a test for protecting noncommercial speech; in commercial speech, we tolerate a lot more potential chill to protect consumers.

As a practical matter, plaintiffs here are better positioned to avoid Mead Johnson than some other plaintiffs because they plead that the implication comes from the entire marketing campaign, not from a single word whose meaning a court could decide consumers were wrong about.


clicking on competitor's ads isn't commercial advertising or promotion

Motogolf.com, LLC v. Top Shelf Golf, LLC, 2022 WL 834790, No. 2:20-cv-00674-APG-EJY (D. Nev. Mar. 21, 2022)

Weird edge case! Motogolf bought online ads on a pay-per-click contract “wherein ads would stop appearing to others if they were clicked a certain number of times in a given period.” Defendants allegedly “sought out Motogolf’s ads and repeatedly clicked on them, causing Motogolf’s ads to disappear sooner and increasing Motogolf’s advertising budget,” and allegedly interfered with its vendor relationships by accusing them of the same behavior. Motogolf sued for violations of the CFAA, the Nevada Computer Crimes Law (NCCL), the Lanham Act, the Nevada Deceptive Trade Protection Act (NDTPA), and Nevada’s Racketeer Influenced and Corrupt Organizations (RICO) law, and for intentional interference with contractual relations and intentional interference with prospective economic advantage.

Previously: The CFAA and NCCL claims were kicked out Motogolf had not plausibly alleged the defendants accessed Motogolf’s website without authorization. Intentional interference with contract went because Motogolf had not identified any specific vendor that the defendants allegedly interfered with. NDTPA and Lanham Act claims were dismissed because Motogolf didn’t plausibly allege the defendants’ click activity was likely to deceive or cause confusion. Nevada RICO failed because Motogolf had not plausibly alleged that the defendants’ conduct involved taking property.

Motogolf filed an amended complaint; the court allowed the CFAA amendment to allege disruption of its website.  But the Lanham Act claim still failed, even explicitly styled as § 1125(a)(1)(B), not § 1125(a)(1)(A).

“Motogolf alleges that by clicking on the ads, the defendants misrepresented that they were legitimate potential customers of Motogolf.” But clicking on an ad is not plausibly commercial advertising or promotion. “There is no allegation that the defendants’ click activity is communicated to any consumers, much less widely disseminated to the purchasing public.” [Wouldn’t the relevant “public” be Motogolf, in this theory? So the false clicks would be disseminated to them, though I agree that it doesn’t really fit the false advertising model. I think this likely fits into the category of commercial conduct--possibly not even speech from a First Amendment perspective, like contracts aren't--but not commercial advertising or promotion, though not really for the ordinary reasons given.] And even if it were commercial advertising, “there is no allegation that the false statement is about the defendants’ own products or Motogolf’s products.” A misrepresentation of oneself as a potential consumer isn’t about products. [Is it about “commercial activities,” the oft-forgotten phrase in §43(a)(1)(B)?] “And because they are misrepresenting themselves as consumers to Motogolf only, they are not making a material representation that is likely to influence other consumers’ purchasing decisions.” [Citing Lexmark; again, the gist seems right, but there does seem to be economic injury “flowing directly from the deception wrought” by defendant’s conduct.]